1. Thomas Enzler*, Arnon P. Kater*, Weizhou Zhang*, George F. Widhopf II, Han-Yu Chuang, Jason Lee, Esther Avery, Carlo M. Croce, Michael Karin, Thomas J. Kipps. Chronic B-Cell leukemia of Eµ-TCL1 transgenic mice undergoes rapid cell-turnover that can be offset by extrinsic CD257 to accelerate disease progression. Blood. 2009, 114(20):4469-76. PMID: 19755673. (* equal contribution). Impact factor: 9.900.
2. Weizhou Zhang*, Arnon P. Kater*, Han-Yu Chuang, Thomas Enzler, George F. Widhopf II, Danelle F. James, Ping-Hui Tseng, Carl Hoh, Harvey Herschman, Thomas J. Kipps, Michael Karin. B cell activating factor and c-Myc regulate progression of B cell chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America. 2010, Nov 2;107(44):18956-60. PMID: 20956327; PMCID: PMC2973856. Impact factor: 10.591.
3. Wei Tan*, Weizhou Zhang*, Amy Strasner, Sergei Grivennikov, Robert M. Hoffman, Jin Q. Cheng, Michael Karin. Tumor infiltrating CD4+ T cells stimulate mammary/breast cancer metastasis through activation of RANKL-RANK signaling. Nature. 2011, Feb 24;470(7335):548-53. (*equal contribution) PMID: 21326202; PMCID: PMC3166217.
4. Weizhou Zhang, Wei Tan, Xuefeng Wu, Maxim Poustovoitov, Amy Strasner, Wei Li, Nicholas Borcherding, Majid Ghassemian, and Michael Karin. A NIK-IKKα module expands ErbB2-induced tumor- initiating cells by stimulating nuclear export of p27/Kip1. Cancer Cell. 2013 May 13;23(5):647-59. PMID: 23602409. PMCID: PMC3981467.
5. Nicholas Borcherding, David Kusner, Ryan Kolb, Qing Xie, Wei Li, Gabriel Velez, Ryan Askeland, Ronald J. Weigel, Weizhou Zhang*. Paracrine Wnt5a signaling inhibits the expansion of tumor-initiating cells. Cancer Res. 2015 May 15;75(10):1972-82. PMID: 25769722; PMCID: PMC4433621. (*Corresponding author).
6. Ryan Kolb, Liem Phan, Nicholas Borcherding, Yinghong Liu, Fang Yuan, Ann M Janowski, Qing Xie, Kathleen R Markan, Wei Li, Matthew J Potthoff, Enrique Fuentes-Mattei, Lesley G Ellies, Michael Knudsen, Mong-Hong Lee, Sai-Ching Jim Yeung, Cassel L Suzanne, Fayyaz S Sutterwala, Weizhou Zhang. Obesity-associated NLRC4 inflammasome promotes angiogenesis in breast cancer. Nature Communications. 2016 Oct 6; 7:13007. PMID: 27708283. PMCID: PMC5059727. Impact factor: 11.05.
7. Nicholas Borcherding, Kimberly Cole, Paige Kluz, Michael Jorgensen, Ryan Kolb, Andrew Bellizzi, Weizhou Zhang. Reevaluating E-Cadherin and B-Catenin: a pan-cancer proteomic approach with an emphasis on breast cancer. The American Journal of Pathology. 2018 Aug;188(8):1910-1920. PMID: 29879416; PMCID: PMC6119824. Impact factor: 4.206.
8. Ryan Kolb, Paige Kluz, Zhen Wei Tan, Nicholas Borcherding, Nicholas Bormann, Ajaykumar Vishwakarma, Louis Balcziak, Pengcheng Zhu, Brandon SJ. Davies, Francois Gourranc, Ling-Zhi Liu, Xin Ge, Bing-Hua Jiang, Katherine Gibson-Corley, Aloysius Klingelhutz, Daniel J. Kelpsch, Tina L. Tootle, Khaled Elmasry, Ahmed S. Ibrahim, Mohamed Al-Shabrawey, Nguan Soon Tan, Fayyaz S. Sutterwala, Xian Shen, Weizhou Zhang. Obesity-associated inflammation promotes angiogenesis via angiopoietin-like 4. Oncogene. 2019 Mar;38(13):2351-2363. PMID: 30518876 PMCID: PMC6440811. Impact factor: 6.634.
9. Gaurav Pandey, Nicholas Borcherding, Ryan Kolb, Wei Li, Sonia Sugg, Jun Zhang, Dazhi A. Lai, Weizhou Zhang. ROR1 potentiates FGFR signaling in basal-like breast cancer. Cancers (Basel). 2019 May 24;11(5). pii: E718. PMID: 31137681; PMCID: PMC6562526. Impact Factor: 6.162.
10. Sajid Khan, Xuan Zhang, Dongwen Lv, Qi Zhang, Yonghan He, Peiyi Zhang, Yaxia Yuan, Xingui Liu, Dinesh Thummuri, Janet S Wiegand, Jing Pei, Weizhou Zhang, Abhisheak Sharma, Christopher R. McCurdy, Vinitha M. Kuruvilla, Natalia Baran, Adolfo A. Ferrando, Anna Rogojina, Peter J Houghton, Guangcun Huang, Robert Hromas, Marina Konopleva, Guangrong Zheng, and Daohong Zhou. DT2216, a BCL-XL proteolysis targeting chimera, is a safer and more potent antitumor agent than ABT263. Nature Medicine. 2019 Dec;25(12):1938-1947. PMID: 31792461. Impact Factor: 34.848.
11. Paige Kluz, Ryan Kolb, Qing Xie, Nicholas Borcherding, Qi Liu, Linna Wang, Yinan Zhang, Wei Li, Christopher Stipp, Katherine N. Gibson-Corley, Chen Zhao, Hank Heng Qi, Andrew Bellizzi, Andy W. Tao, Sonia Sugg, Ronald J. Weigel, Daohong Zhou, Xian Shen, Weizhou Zhang. CD177 at the crossroads of adherens junction and -Catenin activation. Oncogene. 2020 Feb 10. doi: 10.1038/s41388-020-1203-x. [Epub ahead of print] PMID: 32042113. Impact factor: 6.634.
12. Nicholas Borcherding, Ajaykumar Vishwakarma, Michael S. Chimenti, Purshottam Vishwakarma, Kenneth Nepple, Aliasger Salem, Russell W. Jenkins*, Yousef Zakharia*, Weizhou Zhang*. Mapping the Immune Landscape of Clear Cell Renal Cell Carcinoma by Single-Cell RNA-seq. 2021. Communications Biology. 2021 Jan 27;4(1):122. (* Co-corresponding authors). PMID: 33504936 PMCID: PMC7840906. Impact factor: 4.049.
13. Vivian W. Gu, Edward Cho, Dakota T. Thompson, Victoria C. Cassady, Nicholas Borcherding, Kelsey E. Koch, Vincent T. Wu, Allison W. Lorenzen, Mikhail V. Kulak, Trevor Williams, Weizhou Zhang*, Ronald J. Weigel*. AP-2γ is Required for Maintenance of Pluripotent Mammary Stem Cells. Stem Cell Reports. 2021 Jan 12;16(1):106-119. (*Co-corresponding author). PMID: 33382976 PMCID: PMC7897584. Impact factor: 6.032.
14. Ryan Kolb, Umasankar De, Sajid Khan, Yuewan Luo, Myung-Chul Kim, Haijun Yu, Chaoyan Wu, Jiao Mo, Xin Zhang, Peiyi Zhang, Xuan Zhang, Nicholas Borcherding, Daniel Koppel, Yang-Xin Fu, Song Guo Zheng, Dorina Avram, Guangrong Zheng, Daohong Zhou, Weizhou Zhang. Proteolysis-targeting chimeras against BCL-XL destroy tumor-infiltrating regulatory T cells. 2021. Nature Communications. 2021 Feb 24;12(1):1281. PMID: 33627663 PMCID: PMC7904819. Impact factor: 12.121.
15. Yi Sun, Wei Chen, Robert J. Torphy, Sheng Yao, Gefeng Zhu, Emily N. Miller, Yuki Fujiwara, Linghua Zheng, Sudarshan Anand, Fan Gao, Richard D. Schulick, Weizhou Zhang, Lieping Chen, Yuwen Zhu. The CD93/IGFBP7 pathway contributes to abnormal tumor vasculature to cripple drug delivery and immunotherapy. Science Translational Medicine. 2021 Jul 28;13(604):eabc8922. PMID: 34321321. Impact factor: 16.304.
16. Myung-Chul Kim, Nicholas Borcherding, Kawther K Ahmed, Andrew P Voigt, Ajaykumar Vishwakarma, Ryan Kolb , Paige N Kluz, Gaurav Pandey, Umasankar De, Theodore Drashansky, Eric Y Helm, Xin Zhang, Katherine N Gibson-Corley, Julia Klesney-Tait, Yuwen Zhu, Jinglu Lu, Jinsong Lu, Xian Huang, Hongrui Xiang, Jinke Cheng, Dongyang Wang, Zheng Wang, Jian Tang, Jiajia Hu, Zhengting Wang, Hua Liu, Mingjia Li, Haoyang Zhuang, Dorina Avram, Daohong Zhou, Rhonda Bacher, Song Guo Zheng, Xuefeng Wu, Yousef Zakharia, Weizhou Zhang. CD177 modulates the function and homeostasis of tumor-infiltrating regulatory T cells. Nature Communications. 2021 Oct 1;12(1):5764. PMID: 34599187. PMCID: PMC8486774.
17. Dongwen Lv, Pratik Pal, Xingui Liu, Qi Zhang, Dinesh Thummuri, Peiyi Zhang, Wanyi Hu, Jing Pei, Yannan Jia, Shuo Zhou, Sajid Khan, Xuan Zhang, Wen Li, Nan Hua, Qingping Yang, Sebastian Arango, Weizhou Zhang, Digant Nayak, Shaun K. Olsen, Susan T. Weintraub, Robert Hromas, Marina Konopleva, Yaxia Yuan, Guangrong Zheng, and Daohong Zhou. Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity. Nature Communications. 2021 Nov 25;12(1):6896. PMID: 34824248. PMCID: PMC8617031
18. Lei Wang, Yufeng Xiao, Yuewan Luo, Rohan P Master, Jiao Mo, Myung-Chul Kim, Yi Liu, Chandra Maharjan, Urvi M Patel, Xiangming Li, Donald Shaffer, Kevin R Guertin, Haoyang Zhuang, Emily Moser, Keiran S. Smalley, Daohong Zhou, Guangrong Zheng, Weizhou Zhang. PROTAC-mediated NR4A1 Degradation as a Novel Strategy for Cancer Immunotherapy. Journal of Experimental Medicine. Accepted for publication, 2024.
19. Myung-Chul Kim, Umasankar De, Nicholas Borcherding, Joon Paek, Nicole Winn, Indraneel Bhattacharyya, Qing Yu, Ryan Kolb, Theodore Drashansky, Akaluck Thatayatikom, Weizhou Zhang, and Seunghee Cha. Unveiling novel transcriptomic profiles and interplay of immune subsets in rare condition of autoimmune childhood Sjögren’s disease. Communications Biology, Accepted. 2024 (co-correspondence).
Book Chapters:
1. Weizhou Zhang, Nicholas Borcherding, Ryan Kolb. Interleukin-1 signaling in tumor microenvironment. Adv Exp Med Biol. 2020; 1240:1-23. doi: 10.1007/978-3-030-38315-2_1. PMID: 32060884.
2. Ryan Kolb, Nicholas Borcherding, Weizhou Zhang. Understanding and targeting human cancer regulatory T cells to improve cancer therapy. T Regulatory Cells in Human Health and Diseases. Adv Exp Med Biol. 2021;1278:229-256. PMID: 33523451.
Patents:
1. Weizhou Zhang, Ryan Kolb. Anti-angiopoietin-like 4 (Angptl4) antibodies and methods of use. 2019. Application Number: 62/927,289.
2. Weizhou Zhang, Guangrong Zheng, Daohong Zhou, Yufeng Xiao, Lei Wang. Targeting nr4a1 using proteolysis targeting chimeras. 2020. Ref. No.: T18293US001.
Complete List of Published Work in MyBibliography (94 total citations):
https://www.ncbi.nlm.nih.gov/myncbi/weizhou.zhang.1/bibliography/public/